ReviewCurrent opinion in lipidology2012
Phospholipase A(2) enzymes in metabolic and cardiovascular diseases.
Review in Current opinion in lipidology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 84 citations in OpenAlex.
- Impact of Intended Isocaloric Early versus Late Time-Restricted Eating on Plasma Lipidome in Women with Overweight or Obesity: Secondary Analysis of the ChronoFast Trial.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Trial
- Association between polymorphisms in phospholipase A2 genes and the plasma triglyceride response to an n-3 PUFA supplementation: a clinical trial.Lipids in health and disease · 2015Trial
- Dynamic Structural Adaptation and Molecular Response of the Digestive Organs During Feed Domestication inAnimals : an open access journal from MDPI · 2026Article
- Association of Disease-Modifying Antirheumatic Drugs (DMARDs) with Cardiovascular Diseases: Evidence from a Drug Target Mendelian Randomization Study.Global heart · 2026Article
- Proteomic Exploration of L1CAMInternational journal of molecular sciences · 2025Article
- Lipidome disruption in Alzheimer's disease brain: detection, pathological mechanisms, and therapeutic implications.Molecular neurodegeneration · 2025Review
- Article
- Application of Clinical Blood Metabogram to Type 2 Diabetes Mellitus.Metabolites · 2024Article
- Transcriptomic analysis of diabetic kidney disease and neuropathy in mouse models of type 1 and type 2 diabetes.Disease models & mechanisms · 2023Article
- Association of lipid composition and unsaturated fatty acids of VLDL with atrial remodeling in metabolic syndrome.Scientific reports · 2023Article
- Decoding the transcriptome of calcified atherosclerotic plaque at single-cell resolution.Communications biology · 2022Article
- Peroxiredoxins as Potential Targets for Cardiovascular Disease.Antioxidants (Basel, Switzerland) · 2021Review
- The phospholipase A2 family's role in metabolic diseases: Focus on skeletal muscle.Physiological reports · 2021Review
- A Representative GIIA Phospholipase ABiomolecules · 2020Article
- Analysis of the uterine lumen in fertility-classified heifers: I. Glucose, prostaglandins, and lipids†.Biology of reproduction · 2020Article
- Genome-wide DNA methylation profiling of human diabetic peripheral neuropathy in subjects with type 2 diabetes mellitus.Epigenetics · 2019Article
- Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases ABiochimica et biophysica acta. Molecular and cell biology of lipids · 2019Review
- Anti-inflammatory therapy for cardiovascular disease.Annals of translational medicine · 2019Review
- Discovery, fine-mapping, and conditional analyses of genetic variants associated with C-reactive protein in multiethnic populations using the Metabochip in the Population Architecture using Genomics and Epidemiology (PAGE) study.Human molecular genetics · 2018Article
- New quinoxalinone inhibitors targeting secreted phospholipase A2 and α-glucosidase.Journal of enzyme inhibition and medicinal chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThe phospholipase A2 (PLA2) family of proteins includes lipolytic enzymes that liberate the sn-2 fatty acyl chains from phospholipids to yield nonesterified fatty acids and lysophospholipids. The purpose of this review is to discuss recent findings showing distinct roles of several of these PLA2 enzymes in inflammatory metabolic diseases such as diabetes and atherosclerosis. RECENT
findingsThe group 1B PLA2 digestion of phospholipids in the intestinal lumen facilitates postprandial lysophospholipid absorption, which suppresses hepatic fatty acid oxidation leading to increased VLDL synthesis, decreased glucose tolerance, and promotion of tissue lipid deposition to accentuate diet-induced hyperlipidemia, diabetes, and obesity. Other secretory PLA2s promote inflammatory metabolic diseases by generating bioactive lipid metabolites to induce inflammatory cytokine production, whereas the major intracellular PLA2s, cPLA2α, and iPLA2, generate arachidonic acid and lysophosphatic acid in response to extracellular stimuli to activate leukocyte chemotactic response. SUMMARY: Each member of the PLA2 family of enzymes serves a distinct role in generating active lipid metabolites that promote inflammatory metabolic diseases including atherosclerosis, hyperlipidemia, obesity, and diabetes. The development of specific drugs that target one or more of these PLA2 enzymes may be novel strategies for treatment of these chronic inflammatory metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.